HA
LGND icon

Harbor Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Harbor Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,405
Closed -$204K – 165
2018
Q4 		$204K Hold
2,405
– – 0.08% 153
2018
Q3 		$412K Hold
2,405
– – 0.13% 108
2018
Q2 		$311K Sell
2,405
-2,244
-48% -$250K 0.1% 135
2018
Q1 		$479K Hold
4,649
– – 0.16% 92
2017
Q4 		$397K Buy
4,649
+2,244
+93% +$194K 0.13% 103
2017
Q3 		$204K Buy
+2,405
New +$190K 0.07% 148

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Harbor Advisors's LGND Position: Q1 2019 in Review

Harbor Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 2,405 shares — an estimated $204K sold.

Harbor Advisors first reported a position in LGND in Q3 2017 and held it in 6 quarters. The position peaked at $479K in Q1 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Harbor Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Harbor Advisors sold 2,405 Ligand Pharmaceuticals shares in Q1 2019, an estimated $204K.
  • Harbor Advisors first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 6 quarters.
  • Harbor Advisors's Ligand Pharmaceuticals position peaked at $479K in Q1 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Harbor Advisors's 13F filing for Q1 2019, filed 15 May 2019.